Si-bone, INC

SI-BONE, Inc. reported robust second quarter 2026 financial results, including ~15% worldwide revenue growth and a significant increase in adjusted EBITDA, leading to an upward revision of its full-year guidance.

SI-BONE, Inc. has amended its lease for its Santa Clara headquarters, extending the term through August 31, 2026, with an option for an additional month, and has reported the outcomes of its annual shareholder meeting, including director elections and auditor ratification.

SI-BONE, Inc. announced first quarter 2026 financial results, showcasing 11.2% worldwide revenue growth and a significant improvement in adjusted EBITDA, leading to an upward revision of its full-year guidance.

SI-BONE, Inc. announced record financial results for Q4 and full year 2025, achieving over 20% worldwide revenue growth and positive adjusted EBITDA, alongside new 2026 guidance and key operational updates.

SI-BONE, Inc. announced preliminary unaudited revenue and cash for Q4 and full year 2025, showing robust growth and net cash generation.

SI-BONE, Inc. reported strong third-quarter 2025 financial results with significant revenue growth and improved profitability, leading to an upward revision of its full-year 2025 guidance.

SI-BONE, Inc. announced a 15.2% increase in revenue for the second quarter of 2026, driven by strong procedural volume growth in the U.S. and expanding international sales.

SI-BONE, Inc. reported its first quarter 2026 financial results, showing an 11.2% increase in revenue to $52.6 million, driven by higher U.S. procedure volumes and expanded product adoption.

SI-BONE, Inc. reported a 20.6% increase in Q3 2025 revenue to $48.7 million and significantly reduced its net loss, driven by expanded product offerings and increased case volumes.

SI-BONE, Inc. reported a significant 21.7% increase in Q2 2025 revenue and a reduced net loss, driven by expanded product offerings and increased U.S. surgical volumes.

SI-BONE, Inc. announces a 25% increase in revenue for the first quarter of 2025, while navigating an ongoing investigation by the U.S. Department of Justice.

SI-BONE, Inc. announced its third-quarter 2024 financial results, highlighting a 19% increase in revenue compared to the same period last year.

SI-BONE, Inc. reported a 20.2% revenue increase to $200.9 million in 2025, driven by expanded product offerings and physician base, despite incurring a net loss of $18.9 million.

SI-BONE, Inc.'s 10-K filing summarizes the company's FY2024 performance, strategic initiatives, and associated risks.

SI-BONE, a medical device company, has entered into a new manufacturing agreement with RMS Company and filed its annual 10-K report, detailing its financial performance and strategic initiatives.

Laura Francis, Chief Executive Officer and a Director of SI-BONE, Inc., sold 14,956 shares of common stock on August 17, 2026.

Michael A. Pisetsky, SVP, Ops & Adm/Chief Legal Ofr of SI-BONE, Inc., sold 3,725 shares of common stock on August 17, 2026.

Anshul Maheshwari, Chief Financial Officer of SI-BONE, Inc., sold 4,665 shares of common stock on August 17, 2026.

Jeffrey W Dunn, a Director of SI-BONE, Inc., sold 20,000 shares of common stock on August 3, 2026 for $18.46 per share.

SI-BONE, Inc. executive Michael A. Pisetsky reported the sale of company stock to cover tax withholding obligations related to restricted stock unit vesting.

SI-BONE, Inc. Chief Financial Officer Anshul Maheshwari sold shares to cover tax obligations related to restricted stock unit vesting.

SI-BONE, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, scheduled for June 4, 2026, highlighting significant 2025 financial and operational achievements.

SIBN has filed its proxy statement for the upcoming 2025 annual meeting, detailing matters for shareholder consideration.

SI-BONE's 2024 saw a 20% revenue increase, significant physician adoption of iFuse procedures, and substantial improvements in net loss and adjusted EBITDA.

SI-BONE, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) regarding its upcoming shareholder meeting.

SI-BONE, Inc. has scheduled its 2024 Annual Meeting of Stockholders for June 25, 2024, and the proxy statement details key business achievements, director nominations, and governance proposals.

Cadian Capital Management, LP, along with its affiliates, has reported beneficial ownership of approximately 7.5% of SI-BONE, Inc.'s common stock as of June 30, 2026.

First Light Asset Management, LLC and Mathew P. Arens have jointly filed a Schedule 13G, reporting beneficial ownership of 18.02% and 18.36% of SI-BONE, Inc. common stock, respectively.

The Vanguard Group reported zero beneficial ownership in SI-BONE Inc. common stock following an internal realignment effective January 12, 2026.

American Century Mutual Funds, Investment Management, and related entities reported beneficial ownership of 5.3% of Si-Bone, Inc.'s common stock as of December 31, 2025.

Brown Advisory and its affiliates have reported a 5.79% beneficial ownership stake in SI-BONE, Inc. common stock as of December 31, 2025.

Champlain Investment Partners, LLC has reported a 4.9% beneficial ownership stake in SI-BONE, Inc. as an investment adviser.